Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Eton Pharmaceuticals Acquires Exclusive U.S. Rights to LIBERVANT® from Aquestive Therapeutics
Acquiring Company
ETON PHARMACEUTICALS
Acquired Company
Aquestive Therapeutics, Inc.
Deer ParkWarrenBiotechnologyHealthcareHealth CarePharmaceuticalBiotechnologyHealthcareHealth CareMedicalTherapeuticsPharmaceuticalBiopharmaDescription
Eton Pharmaceuticals, Inc. has entered into a license agreement with Aquestive Therapeutics, Inc. to acquire exclusive U.S. rights to LIBERVANT® for the treatment of seizure clusters in epilepsy patients. The agreement includes an upfront payment of $10.0 million and potential milestones of up to $47.5 million based on regulatory approvals and commercial sales. Additionally, a supply agreement has been established for the manufacturing of the product, effective for an initial term of 20 years.
Fundz sees it the moment ETON PHARMACEUTICALS makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Aquestive Therapeutics, Inc.?
Aquestive Therapeutics, Inc. was acquired by ETON PHARMACEUTICALS, based in Deer Park. The deal was reported on October 14, 2026. Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. ETON PHARMACEUTICALS is publicly traded (ETON) and operates in Biotechnology.
When did ETON PHARMACEUTICALS acquire Aquestive Therapeutics, Inc.?
ETON PHARMACEUTICALS's acquisition of Aquestive Therapeutics, Inc. was reported on October 14, 2026. Eton Pharmaceuticals, Inc. has entered into a license agreement with Aquestive Therapeutics, Inc. to acquire exclusive U.S. rights to LIBERVANT® for the treatment of seizure clusters in epilepsy patients. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Aquestive Therapeutics, Inc. do?
Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. It is publicly traded (AQST), operating in Biotechnology, and is based in Warren.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.